Review





Similar Products

monoclonal igfbp2  (R&D Systems)
93
R&D Systems monoclonal igfbp2
miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and <t>IGFBP2</t> in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.
Monoclonal Igfbp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal igfbp2/product/R&D Systems
Average 93 stars, based on 1 article reviews
monoclonal igfbp2 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
rabbit anti migfbp2 monoclonal antibody anti igfbp2mab  (Bioss)
93
Bioss rabbit anti migfbp2 monoclonal antibody anti igfbp2mab
miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and <t>IGFBP2</t> in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.
Rabbit Anti Migfbp2 Monoclonal Antibody Anti Igfbp2mab, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti migfbp2 monoclonal antibody anti igfbp2mab/product/Bioss
Average 93 stars, based on 1 article reviews
rabbit anti migfbp2 monoclonal antibody anti igfbp2mab - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
monoclonal igfbp2  (Danaher Inc)
86
Danaher Inc monoclonal igfbp2
miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and <t>IGFBP2</t> in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.
Monoclonal Igfbp2, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal igfbp2/product/Danaher Inc
Average 86 stars, based on 1 article reviews
monoclonal igfbp2 - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier
rabbit monoclonal anti igfbp2  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc rabbit monoclonal anti igfbp2
miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and <t>IGFBP2</t> in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.
Rabbit Monoclonal Anti Igfbp2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal anti igfbp2/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
rabbit monoclonal anti igfbp2 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
rabbit anti igfbp2 monoclonal antibody anti igfbp2mab  (Bioss)
93
Bioss rabbit anti igfbp2 monoclonal antibody anti igfbp2mab
The interfering RNA sequences used for <t> IGFBP2 </t> knockdown.
Rabbit Anti Igfbp2 Monoclonal Antibody Anti Igfbp2mab, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti igfbp2 monoclonal antibody anti igfbp2mab/product/Bioss
Average 93 stars, based on 1 article reviews
rabbit anti igfbp2 monoclonal antibody anti igfbp2mab - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
rabbit monoclonal anti-human igfbp2 antibody  (Clinisciences)
90
Clinisciences rabbit monoclonal anti-human igfbp2 antibody
The interfering RNA sequences used for <t> IGFBP2 </t> knockdown.
Rabbit Monoclonal Anti Human Igfbp2 Antibody, supplied by Clinisciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal anti-human igfbp2 antibody/product/Clinisciences
Average 90 stars, based on 1 article reviews
rabbit monoclonal anti-human igfbp2 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and IGFBP2 in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.

Journal: Molecular Cancer

Article Title: Dynamic altruistic cooperation within breast tumors

doi: 10.1186/s12943-023-01896-7

Figure Lengend Snippet: miR-125b dichotomizes via NF-κB signaling into altruistic fitness benefits and disadvantage. A Schema showing cell cycle process and regulators. Those indicated with red boxes are involved in G1-S transition and which were selected for further investigation as inhibitory targets of miR-125b. B Cell cycle analysis of miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells, or control LNA or miR-125b LNA inhibitor-transfected MDA-MB-231 cells. C Box plots of fold change in enrichment of indicated gene transcripts pulled-down using biotinylated miR-125b. D Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for indicated genes and mimics. E Homogeneous and heterogeneous mixtures of MCF7 (Left) or MDA-MB-468 (Right) were transfected with siRNA against indicated genes, exposed to sublethal 0.8 nM docetaxel, and the RF α measured. Blue or red dotted line/box plot indicate respective levels of RF α for homogenous mixture or heterogenous mixture with control KD. IKBKB gene codes for IKKβ. F Immunoblotting to detect for indicated proteins extracted from indicated cell lines transfected with combination of indicated mimics and siRNAs for IKBKB . G, H Conditioned media was harvested from cell culture of miR-125b m or Control m -transfected MCF-7 cells and analyzed using cytokine array kit (G) and iTRAQ (H). I Immunoblotting to detect CCL28 and IGFBP2 in conditioned media from mimic or LNA inhibitor-transfected, or EGFP reporter-sorted cell fractions of indicated cell lines. Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control m / Control LNA / Mi/EGFP Low ) is shown. See Fig. S F for results of plasmid-transfected MCF7 cells. J Viability of indicated cell lines with indicated exposure to docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. K Percentage change in size of MDA-MB-231 xenografted tumors in NSG mice with indicated treatment of docetaxel and/or neutralizing antibodies to IGFBP2 and/or CCL28. L Immunoblotting to detect for CCL28 and IGFBP2 in conditioned media from indicated cell lines transfected with combination of indicated mimics and siRNA. Ponceau S for protein load normalization. Quantification of band intensities (relative to first band of each set) is shown. M RS α of homogeneous and heterogeneous mixture of MCF7 (Left) or MDA-MB-468 (Right) cells transfected with indicated siRNA and exposed to indicated docetaxel concentration. N Schema showing proposed mechanism of how miR-125b dichotomizes into fitness benefit and disadvantage of cancer cell altruism. O Schematic showing the different components of the NF-κB signaling pathway and how the oncogenic (fitness benefits) and tumor suppressive (fitness disadvantage) events may be mediated by different parts of the same signaling pathway. Experiment repeated two times, representative result shown (B,F,L). Data are mean ± s.d. from three independent biological sets of triplicates (C,D,E,M). Experiment performed once (G), and results validated in (I). Representative blots from three independent replicates (I). Data are mean ± s.d. from three independent biological duplicates (H) or quadruplicates (J). n = 8-9 independent animals (K). Statistical analysis was performed using two-tailed one sample t -test against 1 (C,M) or 100 (D) or one-way ANOVA with post-hoc Tukey HSD (J,K). NT: no treatment; DTX: docetaxel treatment. Schematic created using Biorender (A,O). Exact P values are shown.

Article Snippet: CD45 (MCA87A647; Biorad), EpCAM (324206; BioLegend), digoxigenin (DIG) ( 11093274910 ; Roche), GFP (2555; Cell Signaling Technology), polyclonal IGFBP2 (3922; Cell Signaling Technology), monoclonal IGFBP2 (ab109284; Abcam), monoclonal IGFBP2 (MAB6741-SP; R&D Systems), monoclonal CCL28 (ab192600; Abcam), polyclonal CCL28 (ab196567; Abcam), monoclonal CCL28 (MAB717-SP; R&D Systems), monoclonal CCL28 (sc-376654, Santa Cruz Biotechnology), Bak1 (12105; Cell Signaling Technology), beta actin (sc-47778; Santa Cruz), H3ac (61637; Active Motif), GAPDH (sc-137179; Santa Cruz), histone H4ac (39243; Active Motif), PCAF (3378; Cell Signaling Technology), KLF2 (sc-28675X; Santa Cruz), Cas9 (61757; Active Motif), ChIP negative control IgG (53026; Active Motif), luciferase (NB600-307; Novus Biologicals), IGF-1R (AF-305-NA; R&D Systems), integrin α5 (AF1864; R&D Systems), integrin β1 (AF-1778-SP; R&D Systems), integrin αV (ab94704; Abcam), integrin β3 (AF-2266-SP; R&D Systems), integrin α2b (ab63983; abcam), CCR10 (MAB3478; R&D Systems), CCR3 (PAB13065; Abnova), CD24 (311118; BioLegend), CCNA2 (4656, Cell Signaling Technology).

Techniques: Cell Cycle Assay, Control, Transfection, Luciferase, Mutagenesis, Construct, Western Blot, Cell Culture, Multiplex sample analysis, Plasmid Preparation, Concentration Assay, Two Tailed Test

Altruistic cancer cells regenerate via epigenetic mechanism. A Mathematical model explains the persistence of altruistic subclone in breast cancer cell population (Upper), and a spatial model simulates changes in the percentage of altruistic cells over time for hypothesized genetic- and epigenetics-mediated altruism (Lower). Dotted lines link events in upper panel to corresponding points in lower panel. See Supplementary Note & . B Indicated cancer cell lines were sorted according to Mi/EGFP levels and the fluorescence monitored over indicated time. C Mi/EGFP fluorescence of non-sorted MDA-MB-231 miR-125bprom-EGFP cells, treated as indicated, as determined by FACS. D Mi/EGFP Low cells were transfected with indicated siRNAs and the Mi/EGFP fluorescence determined after four days. E Schema showing putative consensus sites for KLF2 binding along the hsa-miR-125b-1 promoter and gRNA targeting sequence of CRISPRi. F Mi/EGFP Low cells were transduced with lentivirus for expression of CRISPRi targeting KBS-1 or non-specific sequence, and Mi/EGFP fluorescence determined after four days. G,H Changes in Mi/EGFP fluorescence as treated in (F) were monitored in indicated cell lines (G). Percentage effect of KBS-1 CRISPRi expression on cell viability relative to control CRISPRi was also measured. Cancer cells were exposed to indicated concentration of docetaxel (H). I MDA-MB-231 miR-125bprom-EGFP cells, as treated in (F), were grown as xenografts in NSG mice. Upper: excised tumors at end point of monitoring period. Lower: Percentage change in tumor size with and without docetaxel treatment. J Immunoblotting to detect for IGFBP2 and CCL28 in conditioned media from MDA-MB-231 miR-125bprom-EGFP cells as treated in (F) and used to establish xenograft model for (I). Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control CRISPRi) is shown. Experiments repeated two times (B, C, D, F, G, H, J). Representative data are shown for (J). Mean percentage ± s.d. cells for technical triplicates of representative set are shown in same colours as corresponding histograms (C, D, F, G) or in black only (B). Data are mean ± s.d. from two independent biological sets of triplicates (H). n = 4 independent animals per group (I). Statistical analysis was performed using two-tailed one sample t -test against 0 (H) and two-tailed unpaired t -test (I lower). NT: no treatment; DTX: docetaxel treatment. Exact P values are shown

Journal: Molecular Cancer

Article Title: Dynamic altruistic cooperation within breast tumors

doi: 10.1186/s12943-023-01896-7

Figure Lengend Snippet: Altruistic cancer cells regenerate via epigenetic mechanism. A Mathematical model explains the persistence of altruistic subclone in breast cancer cell population (Upper), and a spatial model simulates changes in the percentage of altruistic cells over time for hypothesized genetic- and epigenetics-mediated altruism (Lower). Dotted lines link events in upper panel to corresponding points in lower panel. See Supplementary Note & . B Indicated cancer cell lines were sorted according to Mi/EGFP levels and the fluorescence monitored over indicated time. C Mi/EGFP fluorescence of non-sorted MDA-MB-231 miR-125bprom-EGFP cells, treated as indicated, as determined by FACS. D Mi/EGFP Low cells were transfected with indicated siRNAs and the Mi/EGFP fluorescence determined after four days. E Schema showing putative consensus sites for KLF2 binding along the hsa-miR-125b-1 promoter and gRNA targeting sequence of CRISPRi. F Mi/EGFP Low cells were transduced with lentivirus for expression of CRISPRi targeting KBS-1 or non-specific sequence, and Mi/EGFP fluorescence determined after four days. G,H Changes in Mi/EGFP fluorescence as treated in (F) were monitored in indicated cell lines (G). Percentage effect of KBS-1 CRISPRi expression on cell viability relative to control CRISPRi was also measured. Cancer cells were exposed to indicated concentration of docetaxel (H). I MDA-MB-231 miR-125bprom-EGFP cells, as treated in (F), were grown as xenografts in NSG mice. Upper: excised tumors at end point of monitoring period. Lower: Percentage change in tumor size with and without docetaxel treatment. J Immunoblotting to detect for IGFBP2 and CCL28 in conditioned media from MDA-MB-231 miR-125bprom-EGFP cells as treated in (F) and used to establish xenograft model for (I). Ponceau S was used to visualize protein load. Quantification of band intensities (relative to Control CRISPRi) is shown. Experiments repeated two times (B, C, D, F, G, H, J). Representative data are shown for (J). Mean percentage ± s.d. cells for technical triplicates of representative set are shown in same colours as corresponding histograms (C, D, F, G) or in black only (B). Data are mean ± s.d. from two independent biological sets of triplicates (H). n = 4 independent animals per group (I). Statistical analysis was performed using two-tailed one sample t -test against 0 (H) and two-tailed unpaired t -test (I lower). NT: no treatment; DTX: docetaxel treatment. Exact P values are shown

Article Snippet: CD45 (MCA87A647; Biorad), EpCAM (324206; BioLegend), digoxigenin (DIG) ( 11093274910 ; Roche), GFP (2555; Cell Signaling Technology), polyclonal IGFBP2 (3922; Cell Signaling Technology), monoclonal IGFBP2 (ab109284; Abcam), monoclonal IGFBP2 (MAB6741-SP; R&D Systems), monoclonal CCL28 (ab192600; Abcam), polyclonal CCL28 (ab196567; Abcam), monoclonal CCL28 (MAB717-SP; R&D Systems), monoclonal CCL28 (sc-376654, Santa Cruz Biotechnology), Bak1 (12105; Cell Signaling Technology), beta actin (sc-47778; Santa Cruz), H3ac (61637; Active Motif), GAPDH (sc-137179; Santa Cruz), histone H4ac (39243; Active Motif), PCAF (3378; Cell Signaling Technology), KLF2 (sc-28675X; Santa Cruz), Cas9 (61757; Active Motif), ChIP negative control IgG (53026; Active Motif), luciferase (NB600-307; Novus Biologicals), IGF-1R (AF-305-NA; R&D Systems), integrin α5 (AF1864; R&D Systems), integrin β1 (AF-1778-SP; R&D Systems), integrin αV (ab94704; Abcam), integrin β3 (AF-2266-SP; R&D Systems), integrin α2b (ab63983; abcam), CCR10 (MAB3478; R&D Systems), CCR3 (PAB13065; Abnova), CD24 (311118; BioLegend), CCNA2 (4656, Cell Signaling Technology).

Techniques: Fluorescence, Transfection, Binding Assay, Sequencing, Transduction, Expressing, Control, Concentration Assay, Western Blot, Two Tailed Test

Lateral inhibition maintains a sparse spatial organization of altruists. A Immunoblotting to detect indicated proteins extracted from Mi/EGFP High and Mi/EGFP Low fractions from indicated cancer cell lines. B,C Mi/EGFP Low and Mi/EGFP High cells from indicated cancer cell lines were exposed to conditioned media harvested from separate batches of Mi/EGFP Low and Mi/EGFP High cells. After four days, the formers’ fluorescence levels were analyzed by FACS (B) and extracted protein of exposed Mi/EGFP Low cell studied by immunoblotting (C). D, E Mi/EGFP Low cells from indicated cell lines were treated with indicated recombinant proteins in combination with neutralizing antibodies and the fluorescence level analyzed by FACS after four days. F-H Mi/EGFP Low cell fractions from indicated cancer cell lines, transfected with control or GAB1 siRNA, were exposed to recombinant IGFBP2 or CCL28. After four days, their fluorescence levels were analyzed by FACS (F, IGFBP2; G, CCL28) and their extracted protein by immunoblotting (H). CM-R: Mi/EGFP Low recipient cells exposed to recombinant protein. I Box plots of fold change in enrichment of GAB1 mRNA pulled-down using biotinylated miR-125b mimics. J Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for GAB1 and indicated mimics. WT: wild type. K Immunoblotting to detect expression of indicated proteins extracted from miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells with or without docetaxel treatment (Upper), or miR-125b LNA-inhibitor- or control-LNA-transfected MDA-MB-231 or MDA-MB-415 cells (Lower). L,M Schema of lateral inhibition model mediated by diffusible IGFBP2 and CCL28 secreted by miR-125b High altruists. Upon exposure to IGFBP2 and CCL28, heightened PI3K-AKT signaling is induced in the recipient cells, resulting in reduction in miR-125b expression and adoption of the non-altruistic social fate (L). Hypothesized level of the diffusible proteins, extent of PI3K activation and probability of altruist arising as the distance from altruist increases is depicted, in association with the altruist’s ability to influence social fates beyond the immediate neighboring cells (M). N Simulation of lateral inhibition dynamics showing pattern generation when diffusion coefficient d = 1 (as in the case of Notch-Delta signaling) and d>1 (mediated by diffusible proteins such as IGFBP2 and CCL28) (Left column). Spatial patterns of Mi/EGFP High and Mi/EGFP Low cells in indicated cell lines, with or without IGFBP2 & CCL28 antibodies treatment, are shown (Center and Right columns). Experiments repeated two times, representative data are shown for (A-H, K, N). Mean percentage ± s.d. cells for technical triplicates of representative set are shown in same colour as corresponding histograms (B,D-G). Data are mean ± s.d. from three independent biological sets of triplicates (I, J). Statistical analysis was performed using two-tailed one sample t -test against 1 (I) or 100 (J). NT: no treatment; DTX: docetaxel treatment. Exact P values are shown

Journal: Molecular Cancer

Article Title: Dynamic altruistic cooperation within breast tumors

doi: 10.1186/s12943-023-01896-7

Figure Lengend Snippet: Lateral inhibition maintains a sparse spatial organization of altruists. A Immunoblotting to detect indicated proteins extracted from Mi/EGFP High and Mi/EGFP Low fractions from indicated cancer cell lines. B,C Mi/EGFP Low and Mi/EGFP High cells from indicated cancer cell lines were exposed to conditioned media harvested from separate batches of Mi/EGFP Low and Mi/EGFP High cells. After four days, the formers’ fluorescence levels were analyzed by FACS (B) and extracted protein of exposed Mi/EGFP Low cell studied by immunoblotting (C). D, E Mi/EGFP Low cells from indicated cell lines were treated with indicated recombinant proteins in combination with neutralizing antibodies and the fluorescence level analyzed by FACS after four days. F-H Mi/EGFP Low cell fractions from indicated cancer cell lines, transfected with control or GAB1 siRNA, were exposed to recombinant IGFBP2 or CCL28. After four days, their fluorescence levels were analyzed by FACS (F, IGFBP2; G, CCL28) and their extracted protein by immunoblotting (H). CM-R: Mi/EGFP Low recipient cells exposed to recombinant protein. I Box plots of fold change in enrichment of GAB1 mRNA pulled-down using biotinylated miR-125b mimics. J Relative luciferase activities of HEK293T cells following transfection of wild-type or mutant reporter construct for GAB1 and indicated mimics. WT: wild type. K Immunoblotting to detect expression of indicated proteins extracted from miR-125b m or Control m -transfected MCF7 or MDA-MB-468 cells with or without docetaxel treatment (Upper), or miR-125b LNA-inhibitor- or control-LNA-transfected MDA-MB-231 or MDA-MB-415 cells (Lower). L,M Schema of lateral inhibition model mediated by diffusible IGFBP2 and CCL28 secreted by miR-125b High altruists. Upon exposure to IGFBP2 and CCL28, heightened PI3K-AKT signaling is induced in the recipient cells, resulting in reduction in miR-125b expression and adoption of the non-altruistic social fate (L). Hypothesized level of the diffusible proteins, extent of PI3K activation and probability of altruist arising as the distance from altruist increases is depicted, in association with the altruist’s ability to influence social fates beyond the immediate neighboring cells (M). N Simulation of lateral inhibition dynamics showing pattern generation when diffusion coefficient d = 1 (as in the case of Notch-Delta signaling) and d>1 (mediated by diffusible proteins such as IGFBP2 and CCL28) (Left column). Spatial patterns of Mi/EGFP High and Mi/EGFP Low cells in indicated cell lines, with or without IGFBP2 & CCL28 antibodies treatment, are shown (Center and Right columns). Experiments repeated two times, representative data are shown for (A-H, K, N). Mean percentage ± s.d. cells for technical triplicates of representative set are shown in same colour as corresponding histograms (B,D-G). Data are mean ± s.d. from three independent biological sets of triplicates (I, J). Statistical analysis was performed using two-tailed one sample t -test against 1 (I) or 100 (J). NT: no treatment; DTX: docetaxel treatment. Exact P values are shown

Article Snippet: CD45 (MCA87A647; Biorad), EpCAM (324206; BioLegend), digoxigenin (DIG) ( 11093274910 ; Roche), GFP (2555; Cell Signaling Technology), polyclonal IGFBP2 (3922; Cell Signaling Technology), monoclonal IGFBP2 (ab109284; Abcam), monoclonal IGFBP2 (MAB6741-SP; R&D Systems), monoclonal CCL28 (ab192600; Abcam), polyclonal CCL28 (ab196567; Abcam), monoclonal CCL28 (MAB717-SP; R&D Systems), monoclonal CCL28 (sc-376654, Santa Cruz Biotechnology), Bak1 (12105; Cell Signaling Technology), beta actin (sc-47778; Santa Cruz), H3ac (61637; Active Motif), GAPDH (sc-137179; Santa Cruz), histone H4ac (39243; Active Motif), PCAF (3378; Cell Signaling Technology), KLF2 (sc-28675X; Santa Cruz), Cas9 (61757; Active Motif), ChIP negative control IgG (53026; Active Motif), luciferase (NB600-307; Novus Biologicals), IGF-1R (AF-305-NA; R&D Systems), integrin α5 (AF1864; R&D Systems), integrin β1 (AF-1778-SP; R&D Systems), integrin αV (ab94704; Abcam), integrin β3 (AF-2266-SP; R&D Systems), integrin α2b (ab63983; abcam), CCR10 (MAB3478; R&D Systems), CCR3 (PAB13065; Abnova), CD24 (311118; BioLegend), CCNA2 (4656, Cell Signaling Technology).

Techniques: Inhibition, Western Blot, Fluorescence, Recombinant, Transfection, Control, Luciferase, Mutagenesis, Construct, Expressing, Activation Assay, Diffusion-based Assay, Two Tailed Test

Breast tumor as a dynamic social system manifesting altruistic cooperation. A In altruistic cooperation, a small subpopulation of altruistic cells (blue) confers communal protection against taxane exposure by secreting trophic factors (IGFBP2 and CCL28) that activate PI3K/AKT signaling and thus leading to heightened chemotolerance in neighboring cells (yellow). During post-treatment expansion phase, the altruistic subpopulation, saddled with a fitness disadvantage due to miR-125b-mediated cell cycle impediment, risks becoming extinct due to competition from the faster growing neighboring non-altruists. B Conferment of survival benefits to others (an oncogenic event) and incurring of fitness cost to self (a tumor suppressive event), both of which are defining attributes of altruism, are found to be commonly mediated by heightened miR-125b expression, via differential NF-κB signaling, in the altruistic cancer cells. C The altruistic subpopulation persists, due to phenotypic conversion from the neighboring non-altruists via a KLF2/PCAF-mediated epigenetic mechanism acting on the promoter of the hsa-miR-125b-1 gene. D The tumor cell population actively self-organizes via a lateral inhibition mechanism mediated by IGFBP2/CCL28-induced GAB1-PI3K-AKT-miR-125b signaling circuit. This limits the altruistic subpopulation to a minority presence and a sparse spatial arrangement. A closer look at the lateral inhibition model (below) shows inhibition of GAB1 by high miR-125b expression in the altruist, which prevents self-activation of PI3K/AKT by the altruists-secreted IGFBP2 and CCL28, thus averting self-benefiting and instability of the altruistic phenotype. E The lateral inhibition mechanism, coupled with epigenetic regenerability of the altruists, permits stable co-existence of functionally distinct subpopulations: an altruistic miR-125b High minority confers costly communal protection during chemotherapeutic crisis while the miR-125b Low majority undergoes aggressive proliferation post-crisis to re-colonize the tumor. Cooperation between these different phenotypes suggests the existence of division of labor, a hallmark of complex biological societies, within the breast tumor. F One possible explanation of the origin of altruistic tumor society is evolution from a homogeneous population of generalist cancer cells. The composition of the resulting altruistic society of cancer cells can theoretically be perturbed with varying ecological consequences. Without epigenetic regeneration of altruists, non-altruists or “cheats” would dominate and deplete existing resources, leading to a situation called the “tragedy of the commons” . Conversely, without lateral inhibition, altruists would dominate the population, hence inflicting a fitness burden on the tumor. Breast tumor may thus constitute a potential model to study how tumor-specific ecological factors can affect evolution and manifestation of altruistic cooperation. G Examples of altruistic social systems and how the social dynamics is regulated. Above: In honeybee ( Apis Mellifera ), the queen bee secretes primer pheromone such as CHCs and other glandular compounds that suppress worker ovarian development, thus maintaining the workers as reproductive altruists . In Dictyostelium amoeba, the pre-spores secrete differentiation-inducing factor-1 (DIF-1) to prevent the altruistic pre-stalk cells from developing into spores, thus maintaining a 80:20 spore-to-stalk cell ratio in the fruiting body that is formed eventually . Such secretion-mediated regulation of cell fate is similarly observed in the altruistic breast cancer cells. Below: Epigenetic regulation is known to underlie behavioral plasticity in Apis Mellifera , and we likewise observed how epigenetic mechanism regulates social fate plasticity in breast cancer cells

Journal: Molecular Cancer

Article Title: Dynamic altruistic cooperation within breast tumors

doi: 10.1186/s12943-023-01896-7

Figure Lengend Snippet: Breast tumor as a dynamic social system manifesting altruistic cooperation. A In altruistic cooperation, a small subpopulation of altruistic cells (blue) confers communal protection against taxane exposure by secreting trophic factors (IGFBP2 and CCL28) that activate PI3K/AKT signaling and thus leading to heightened chemotolerance in neighboring cells (yellow). During post-treatment expansion phase, the altruistic subpopulation, saddled with a fitness disadvantage due to miR-125b-mediated cell cycle impediment, risks becoming extinct due to competition from the faster growing neighboring non-altruists. B Conferment of survival benefits to others (an oncogenic event) and incurring of fitness cost to self (a tumor suppressive event), both of which are defining attributes of altruism, are found to be commonly mediated by heightened miR-125b expression, via differential NF-κB signaling, in the altruistic cancer cells. C The altruistic subpopulation persists, due to phenotypic conversion from the neighboring non-altruists via a KLF2/PCAF-mediated epigenetic mechanism acting on the promoter of the hsa-miR-125b-1 gene. D The tumor cell population actively self-organizes via a lateral inhibition mechanism mediated by IGFBP2/CCL28-induced GAB1-PI3K-AKT-miR-125b signaling circuit. This limits the altruistic subpopulation to a minority presence and a sparse spatial arrangement. A closer look at the lateral inhibition model (below) shows inhibition of GAB1 by high miR-125b expression in the altruist, which prevents self-activation of PI3K/AKT by the altruists-secreted IGFBP2 and CCL28, thus averting self-benefiting and instability of the altruistic phenotype. E The lateral inhibition mechanism, coupled with epigenetic regenerability of the altruists, permits stable co-existence of functionally distinct subpopulations: an altruistic miR-125b High minority confers costly communal protection during chemotherapeutic crisis while the miR-125b Low majority undergoes aggressive proliferation post-crisis to re-colonize the tumor. Cooperation between these different phenotypes suggests the existence of division of labor, a hallmark of complex biological societies, within the breast tumor. F One possible explanation of the origin of altruistic tumor society is evolution from a homogeneous population of generalist cancer cells. The composition of the resulting altruistic society of cancer cells can theoretically be perturbed with varying ecological consequences. Without epigenetic regeneration of altruists, non-altruists or “cheats” would dominate and deplete existing resources, leading to a situation called the “tragedy of the commons” . Conversely, without lateral inhibition, altruists would dominate the population, hence inflicting a fitness burden on the tumor. Breast tumor may thus constitute a potential model to study how tumor-specific ecological factors can affect evolution and manifestation of altruistic cooperation. G Examples of altruistic social systems and how the social dynamics is regulated. Above: In honeybee ( Apis Mellifera ), the queen bee secretes primer pheromone such as CHCs and other glandular compounds that suppress worker ovarian development, thus maintaining the workers as reproductive altruists . In Dictyostelium amoeba, the pre-spores secrete differentiation-inducing factor-1 (DIF-1) to prevent the altruistic pre-stalk cells from developing into spores, thus maintaining a 80:20 spore-to-stalk cell ratio in the fruiting body that is formed eventually . Such secretion-mediated regulation of cell fate is similarly observed in the altruistic breast cancer cells. Below: Epigenetic regulation is known to underlie behavioral plasticity in Apis Mellifera , and we likewise observed how epigenetic mechanism regulates social fate plasticity in breast cancer cells

Article Snippet: CD45 (MCA87A647; Biorad), EpCAM (324206; BioLegend), digoxigenin (DIG) ( 11093274910 ; Roche), GFP (2555; Cell Signaling Technology), polyclonal IGFBP2 (3922; Cell Signaling Technology), monoclonal IGFBP2 (ab109284; Abcam), monoclonal IGFBP2 (MAB6741-SP; R&D Systems), monoclonal CCL28 (ab192600; Abcam), polyclonal CCL28 (ab196567; Abcam), monoclonal CCL28 (MAB717-SP; R&D Systems), monoclonal CCL28 (sc-376654, Santa Cruz Biotechnology), Bak1 (12105; Cell Signaling Technology), beta actin (sc-47778; Santa Cruz), H3ac (61637; Active Motif), GAPDH (sc-137179; Santa Cruz), histone H4ac (39243; Active Motif), PCAF (3378; Cell Signaling Technology), KLF2 (sc-28675X; Santa Cruz), Cas9 (61757; Active Motif), ChIP negative control IgG (53026; Active Motif), luciferase (NB600-307; Novus Biologicals), IGF-1R (AF-305-NA; R&D Systems), integrin α5 (AF1864; R&D Systems), integrin β1 (AF-1778-SP; R&D Systems), integrin αV (ab94704; Abcam), integrin β3 (AF-2266-SP; R&D Systems), integrin α2b (ab63983; abcam), CCR10 (MAB3478; R&D Systems), CCR3 (PAB13065; Abnova), CD24 (311118; BioLegend), CCNA2 (4656, Cell Signaling Technology).

Techniques: Expressing, Inhibition, Activation Assay

The interfering RNA sequences used for IGFBP2 knockdown.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: The interfering RNA sequences used for IGFBP2 knockdown.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Sequencing

(A) An association of the enrichment score of the MES signature with the expression of IGFBP2 using the TCGA-gliomas database. R = Pearson’s correlation coefficient. (B-C) Effect of IGFBP2 knockdown with shRNA (IGFBP2KD) (B) or an anti-IGFBP2 antibody (anti-IGFBP2) (C) on mesenchymal marker protein levels in mouse GBM GL261 cells. (D) Effect of overexpressed IGFBP2 wildtype (IGFBP2OE) or mutant (IGFBP2mt) with the change of RGD to RGE on mesenchymal marker protein levels. The experiments were repeated at least three times. A statistical significance was calculated using an unpaired Welch’s t test. * P<0.05, ** P<0.01, *** P<0.001.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: (A) An association of the enrichment score of the MES signature with the expression of IGFBP2 using the TCGA-gliomas database. R = Pearson’s correlation coefficient. (B-C) Effect of IGFBP2 knockdown with shRNA (IGFBP2KD) (B) or an anti-IGFBP2 antibody (anti-IGFBP2) (C) on mesenchymal marker protein levels in mouse GBM GL261 cells. (D) Effect of overexpressed IGFBP2 wildtype (IGFBP2OE) or mutant (IGFBP2mt) with the change of RGD to RGE on mesenchymal marker protein levels. The experiments were repeated at least three times. A statistical significance was calculated using an unpaired Welch’s t test. * P<0.05, ** P<0.01, *** P<0.001.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Expressing, shRNA, Marker, Mutagenesis

(A-C) The mouse splenocytes (SPCs) were co-cultured with GL261 cells for 6 days and then collected to analyze the number of CD8 + and CD4 + T cells by fluorescence activated cell sorting (FACS) under the setting of IGFBP2KD (A), anti-IGFBP2 (B) or overexpressed IGFBP2 and its mutant (C). The experiments were repeated at least three times. Representative IHC images of CD8 + T cells (D-E), CD163 + M2 macrophages (G-H), and pY513-CD19 + cells (J-K) in tumor-bearing brains of mice treated with anti-IGFBP2 or IgG. 100X (left), 400X (right). N = 3. (F, I) The percentage of tumor infiltrating CD8 + T cells (F) and CD163 + M2 macrophages in F4/80 + macrophages (I) analyzed by FACS after anti-IGFBP2 or IgG treatment. N = 5. The data are mean ± SD. A statistical significance was calculated by an unpaired Welch’s t test. * P<0.05, ** p < 0.01, *** p < 0.001.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: (A-C) The mouse splenocytes (SPCs) were co-cultured with GL261 cells for 6 days and then collected to analyze the number of CD8 + and CD4 + T cells by fluorescence activated cell sorting (FACS) under the setting of IGFBP2KD (A), anti-IGFBP2 (B) or overexpressed IGFBP2 and its mutant (C). The experiments were repeated at least three times. Representative IHC images of CD8 + T cells (D-E), CD163 + M2 macrophages (G-H), and pY513-CD19 + cells (J-K) in tumor-bearing brains of mice treated with anti-IGFBP2 or IgG. 100X (left), 400X (right). N = 3. (F, I) The percentage of tumor infiltrating CD8 + T cells (F) and CD163 + M2 macrophages in F4/80 + macrophages (I) analyzed by FACS after anti-IGFBP2 or IgG treatment. N = 5. The data are mean ± SD. A statistical significance was calculated by an unpaired Welch’s t test. * P<0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Cell Culture, Fluorescence, FACS, Mutagenesis

( A) An association of the enrichment score of the MES signature with FcγRIIB expression analyzed by using the TCGA-human glioma database. R = Pearson’s correlation coefficient. (B) Representative IHC images of IGFBP2 protein and phosphorylated FcγRIIB (p-FcγRIIB) levels in human GBMs (hGBMs) or normal brains stained in tissue microarrays. (C) An association of IGFBP2 protein and p-FcγRIIB levels in human GBMs. R, the Pearson correlation coefficient. (D-I), The percentage of p-FcγRIIB + cells in the SPCs after co-cultured with GL261 cells treated with sh1RNA-IGFBP2 (D-E), anti-IGFBP2 (F-G) or overexpressing IGFBP2 or IGFBP2mt (H-I) analyzed by FACS. (J-K), Representative IHC images of p-FcγRIIB staining in tumor-bearing brains treated with anti-IGFBP2 or IgG. N = 3. (L) The percentage of p-FcγRIIB + cells in infiltrating immune cells in GL261 tumors analyzed by FACS. N = 5. The data are mean ± SD. A statistical significance was computed by an unpaired Welch’s t test. * P < 0.05, ** p < 0.01.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: ( A) An association of the enrichment score of the MES signature with FcγRIIB expression analyzed by using the TCGA-human glioma database. R = Pearson’s correlation coefficient. (B) Representative IHC images of IGFBP2 protein and phosphorylated FcγRIIB (p-FcγRIIB) levels in human GBMs (hGBMs) or normal brains stained in tissue microarrays. (C) An association of IGFBP2 protein and p-FcγRIIB levels in human GBMs. R, the Pearson correlation coefficient. (D-I), The percentage of p-FcγRIIB + cells in the SPCs after co-cultured with GL261 cells treated with sh1RNA-IGFBP2 (D-E), anti-IGFBP2 (F-G) or overexpressing IGFBP2 or IGFBP2mt (H-I) analyzed by FACS. (J-K), Representative IHC images of p-FcγRIIB staining in tumor-bearing brains treated with anti-IGFBP2 or IgG. N = 3. (L) The percentage of p-FcγRIIB + cells in infiltrating immune cells in GL261 tumors analyzed by FACS. N = 5. The data are mean ± SD. A statistical significance was computed by an unpaired Welch’s t test. * P < 0.05, ** p < 0.01.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Expressing, Staining, Cell Culture

(A-B) The time course induction of FcγRIIB phosphorylation on CD19 + B cells in SPCs co-cultured with IGFBP2OE GL261 or control cells. The percentage of CD19 L p-FcγRIIB H , CD19 L p-FcγRIIB - , and CD19 H p-FcγRIIB L B cell subsets was analyzed by FACS. L is low, H is high. (C-H) The percentage of p-FcγRIIB + cells in CD19 + B cells after co-cultured with GL261 cells treated with shRNA (C-D), anti-IGFBP2 (E-F) or overexpressing IGFBP2 or its mutant (G-H). (I-J) The percentage of CD19 + p-FcγRIIB + B cells in infiltrating immune cells (I) and p-FcγRIIB + cells in CD19 + B cells in anti-IGFBP2 or IgG tumors analyzed by FACS(J). (K) The ratio of CD19 + B cells versus CD19 + p-FcγRIIB + B cells. (L-M) The percentage of F4/80 + p-FcγRIIB + macrophages in infiltrating immune cells (L) and p-FcγRIIB + cells in F4/80 + macrophages (M) in anti-IGFBP2 or IgG tumors analyzed by FACS. N = 5. The data are mean ± SD. A statistical significance was calculated by an unpaired Welch's t test. * P < 0.05, ** P < 0.01.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: (A-B) The time course induction of FcγRIIB phosphorylation on CD19 + B cells in SPCs co-cultured with IGFBP2OE GL261 or control cells. The percentage of CD19 L p-FcγRIIB H , CD19 L p-FcγRIIB - , and CD19 H p-FcγRIIB L B cell subsets was analyzed by FACS. L is low, H is high. (C-H) The percentage of p-FcγRIIB + cells in CD19 + B cells after co-cultured with GL261 cells treated with shRNA (C-D), anti-IGFBP2 (E-F) or overexpressing IGFBP2 or its mutant (G-H). (I-J) The percentage of CD19 + p-FcγRIIB + B cells in infiltrating immune cells (I) and p-FcγRIIB + cells in CD19 + B cells in anti-IGFBP2 or IgG tumors analyzed by FACS(J). (K) The ratio of CD19 + B cells versus CD19 + p-FcγRIIB + B cells. (L-M) The percentage of F4/80 + p-FcγRIIB + macrophages in infiltrating immune cells (L) and p-FcγRIIB + cells in F4/80 + macrophages (M) in anti-IGFBP2 or IgG tumors analyzed by FACS. N = 5. The data are mean ± SD. A statistical significance was calculated by an unpaired Welch's t test. * P < 0.05, ** P < 0.01.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Cell Culture, shRNA, Mutagenesis

P values in <xref ref-type= Fig 4C–4H ." width="100%" height="100%">

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: P values in Fig 4C–4H .

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques:

( A) Representative T2-weighted MRI of GL261-bearing brains of mice treated with anti-IGFBP2 or IgG after 3 and 5 weeks of GL261cell injection. (B) The tumor growth curve in anti-IGFBP2 and IgG groups. (C) The Kaplan-Meier survival plot of GL261-bearing mice treated with anti-IGFBP2 or IgG. Log-rank test was used to compare the difference of the median survival time between the two groups. N = 5.

Journal: PLoS ONE

Article Title: IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma

doi: 10.1371/journal.pone.0222999

Figure Lengend Snippet: ( A) Representative T2-weighted MRI of GL261-bearing brains of mice treated with anti-IGFBP2 or IgG after 3 and 5 weeks of GL261cell injection. (B) The tumor growth curve in anti-IGFBP2 and IgG groups. (C) The Kaplan-Meier survival plot of GL261-bearing mice treated with anti-IGFBP2 or IgG. Log-rank test was used to compare the difference of the median survival time between the two groups. N = 5.

Article Snippet: For anti-IGFBP2 antibody treatment, 2.0 μg/ml of a rabbit anti-IGFBP2 monoclonal antibody (anti-IGFBP2mAb) (bs-1108R, Bioss) or isotype IgG control (bs-0295P, Bioss) was added to GL261 culture for 3 days and collected for western blotting.

Techniques: Injection